National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 34110 [2013-13373]
Download as PDF
<![CDATA[
34110
Federal Register / Vol. 78, No. 109 / Thursday, June 6, 2013 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
B. Research Objectives
The following are the primary
objectives that FDA/CDER/OCOMM/
DHC seeks to achieve through further
support of this national outreach
campaign: (1) To collaborate with a
large group of public-private partners
that can significantly increase
awareness and outreach far beyond
what FDA would be able to do on its
own to promote increased
understanding and positive actions
among the general public and health
professionals related to this critical
issue; (2) to develop new online
resources and tools for patients; (3) to
educate health care professionals with
strategies to share with patients; (4) to
continually evaluate the campaign to
improve and enhance it; (5) to tailor
campaign messaging to subpopulations
of consumers who may need
adaptations to best inform and educate
them; (6) to further targeted market
outreach through community events and
activities; (7) to develop new campaign
materials for patients and health care
providers; (8) to further widespread
dissemination of campaign materials to
consumers and health care professionals
across the country, including at
pharmacies, community centers,
workplaces, clinic offices, health fairs,
and local events; (9) to provide
counseling and education directly to
consumers about adherence in their
communities, including through the
involvement of students studying
pharmacy, medicine, nursing, and other
health professions; (10) to explore new
media opportunities for dissemination
of the program at the local, State and
national levels, in trade press, online
journals, radio, television, and more;
and (11) to extend outreach through
social media, such as Twitter chats, free
text message reminders, online pledges
through Facebook and Twitter and other
channels.
The following are some specific
objectives that FDA believes can further
enhance the ‘‘Script Your Future’’
campaign: (1) Addition of patient and
family caregiver testimonials to the
campaign Web site; (2) creation of a
custom ‘‘I Will’’ tab on the ‘‘Script Your
Future’’ Facebook page; (3) translation
of the radio public service
announcement from English to Spanish;
(4) development of ‘‘Script Your Futurein-A-Box,’’ a turnkey package
incorporating press background
materials and other elements; and (5)
organization of a public event in fall
2013 and a study to measure the reach
of events, media, and partner
engagement.
VerDate Mar<15>2010
17:35 Jun 05, 2013
Jkt 229001
C. Eligibility Information
Competition is limited to the NCL
because it has unique expertise and
capacity found nowhere else.
Specifically, the FDA/CDER/OCOMM,
DHC, seeks to continue and enhance its
public health mission to educate and
inform the public and health
professions about the importance of
medication adherence by awarding a
grant to the NCL to advance its national
campaign, ‘‘Script Your Future.’’ This
campaign represents a comprehensive,
integrated approach to raise awareness
about the problem of poor medication
adherence, and FDA has served as a key
government stakeholder since 2010.
Because FDA has been a partner in the
formative stages of this campaign and
has seen evidence indicating that it has
already had an impact in helping to
resolve the problem of medication
adherence, FDA seeks to continue
funding new dimensions of the
campaign, especially to serve U.S.
subpopulations of people having low
literacy/health literacy, or who face
health disparities and social and
economic disadvantages.
II. Award Information/Funds Available
A. Award Amount
The total amount of funding for this
grant is $200,000 over 2 years.
Applications budgets will be limited to
$100,000 in the first year and $100,000
in the second year depending on the
availability of funds. The number of
awards anticipated is one individual
award.
B. Length of Support
The term for this grant will begin in
August 2013 for a period of 2 years
through August 15, 2015.
III. Paper Application, Registration,
and Submission Information
To submit a paper application in
response to this FOA, applicants should
first review the full announcement.
Persons interested in applying for a
grant may obtain an application at
https://grants.nih.gov/grants/forms.htm.
For all paper application submissions,
the following steps are required:
• Step 1: Obtain a Dun and Bradstreet
(DUNS) Number
• Step 2: Register With System for
Award Management (SAM)
• Step 3: Register With Electronic
Research Administration (eRA)
Commons
Steps 1 and 2, in detail, can be found
at https://www07.grants.gov/applicants/
organization_registration.jsp. Step 3, in
detail, can be found at https://
commons.era.nih.gov/commons/
PO 00000
Frm 00080
Fmt 4703
Sfmt 9990
registration/registrationInstructions.jsp.
After you have followed these steps,
submit paper applications to: Gladys
Melendez, Grants Management Branch
(HFA–500), Food and Drug
Administration, Rm. 2031, 5630 Fishers
Lane, Rockville, MD 20857.
Dated: June 3, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–13447 Filed 6–5–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: June 26, 2013.
Time: 11:30 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817,
(Telephone Conference Call).
Contact Person: Jay R. Radke, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892–7616, 301–496–2550,
jay.radke@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 31, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–13373 Filed 6–5–13; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\06JNN1.SGM
06JNN1
]]>Agencies
[Federal Register Volume 78, Number 109 (Thursday, June 6, 2013)]
[Notices]
[Page 34110]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-13373]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: June 26, 2013.
Time: 11:30 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6700B Rockledge Drive,
Bethesda, MD 20817, (Telephone Conference Call).
Contact Person: Jay R. Radke, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC
7616, Bethesda, MD 20892-7616, 301-496-2550, jay.radke@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: May 31, 2013.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-13373 Filed 6-5-13; 8:45 am]
BILLING CODE 4140-01-P
